Pfizer was founded in 1849 by
Charles Pfizer and
Charles F. Erhart, two cousins who had immigrated to the United States from
Ludwigsburg, Germany, the year before. The business produced chemical compounds, and was headquartered on Bartlett Street in
Williamsburgh, New York where they produced an
santonin. This was an immediate success, although it was production of
citric acid that led to Pfizer's growth in the 1880s. Pfizer continued to buy property in the area (by now the Williamsburg district of the city of
Brooklyn, New York and beginning in 1898, the
City of Greater New York) to expand its lab and factory, retaining offices on Flushing Avenue until the 1960s; the Brooklyn plant ultimately closed in 2009. Following their success with citric acid, Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) established their main residences in the nearby
Clinton Hill district, known for its concentration of
Gilded Age wealth. Pfizer spent summers in similarly exclusive
Newport, Rhode Island where he died in 1906.
In 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in
Manhattan, presaging the company's expansion to
Chicago a year later. By 1906 sales exceeded $3million.
World War I caused a shortage of
calcium citrate, which Pfizer imported from Italy for the manufacture of citric acid, and the company began a search for an alternative supply. Pfizer chemists learned of a
fungus that ferments sugar to citric acid, and they were able to commercialize production of citric acid from this source in 1919. The company developed expertise in fermentation technology as a result. These skills were applied to the mass production of
World War II in response to the need to treat injured Allied soldiers.
On June 2, 1942, the company incorporated in
1950–1980: Pivot to pharmaceutical research and global expansion
Due to price declines for
penicillin, Pfizer searched for new antibiotics with greater profit potential. Pfizer discovered
oxytetracycline in 1950, and this changed the company from a manufacturer of
fine chemicals to a research-based pharmaceutical company. Pfizer developed a
drug discovery program focused on in vitro synthesis to augment its research in fermentation technology. In 1959, the company established an
animal health division with a 700-acre (2.8 km2) farm and research facility in
Terre Haute, Indiana.
As the area surrounding its
Brooklyn plant fell into decline in the 1970s and 1980s, the company formed a public-private partnership with New York City that encompassed the construction of low- and middle-income housing, the refurbishment of apartment buildings for the homeless and the establishment of a
In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra (
sildenafil) for treating
high blood pressure and
angina, a chest pain associated with
coronary artery disease. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased
erections several days after taking the drug. It was patented in the United States in 1996 and received approval by the
Food and Drug Administration in March 1998. In December 1998, Pfizer hired
Bob Dole as a spokesperson for the drug. The patents for Viagra expired in 2020.
In 1997, the company entered into a co-marketing agreement with
Warner–Lambert for Lipitor (
statin for the treatment of
hypercholesterolemia. Although atorvastatin was the fifth
statin to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in
low-density lipoprotein pattern C (LDL-C) than the other statin drugs. Upon its patent expiration in 2011, Lipitor was the best-selling drug ever, with approximately $125billion in sales over 14.5 years.
On December 3, 2006, Pfizer ceased development of
torcetrapib, a drug that increases production of
HDL, which reduces
LDL thought to be correlated to heart disease. During a
Phase III clinical trial involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the
mortality rate of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1billion developing the failed drug and its stock price dropped 11% on the day of the announcement.
Between 2007 and 2010, Pfizer spent $3.3million on investigations and legal fees and recovered about $5.1million, and had another $5million of pending recoveries from civil lawsuits against makers of
counterfeit prescription drugs. Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for
In July 2008, Pfizer announced 275 job cuts at its manufacturing facility in
Kalamazoo, Michigan. Kalamazoo was previously the world headquarters of
Upjohn Company, which had been acquired as part of Pharmacia.
Acquisitions and mergers
In June 2000, Pfizer acquired Warner-Lambert outright for $116billion. To satisfy conditions imposed by antitrust regulators at the
Federal Trade Commission, Pfizer sold off or transferred stakes in several minor products, including RID (a shampoo for treatment of
head lice, sold to
Bayer) and Warner-Lambert's antidepressant
Celexa (which competes with Zoloft). The acquisition created what was, at the time, the second-largest pharmaceutical company worldwide.
In October 2006, the company announced it would acquire PowerMed.
On October 15, 2009, Pfizer acquired
Wyeth for $68billion in cash and stock, including the assumption of debt, making Pfizer the largest pharmaceutical company in the world. The acquisition of Wyeth provided Pfizer with a
pneumococcal conjugate vaccine, trademarked
Prevnar 13; this is used for the prevention of invasive pneumococcal infections. The introduction of the original, 7-valent version of the vaccine, developed by
Wyeth in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age5 in the United States. Pfizer introduced an improved version of the vaccine in 2010, for which it was granted a patent in India in 2017. Prevnar 13 provides coverage of 13 bacterial variants, expanding beyond the original 7-valent version. By 2012, the rate of invasive infections among children under age5 had been reduced by an additional 50%.
In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in
Sandwich, Kent, which at the time employed 2,400 people. In March 2011, Pfizer acquired
King Pharmaceuticals for $3.6billion in cash. King produced emergency injectables such as the
In June 2016, the company acquired Anacor Pharmaceuticals for $5.2billion, expanding its portfolio in both inflammation and immunology drugs areas. In August 2016, the company made a $40million bid for the assets of BIND Therapeutics, which was in
bankruptcy. The same month, the company acquired Bamboo Therapeutics for $645million, expanding its gene therapy offerings. In September 2016, the company acquired cancer drug-maker
Medivation for $14billion. In October 2016, the company licensed the anti-
CTLA4 monoclonal antibody, ONC-392, from OncoImmune. In November 2016, Pfizer funded a $3,435,600 study with the
CDC Foundation to research "screen-and-treat" strategies for
cryptococcal disease in
Botswana. In December 2016, Pfizer acquired
AstraZeneca's small-molecule antibiotics business for $1.575 billion.
In July 2019, the company acquired Therachon for up to $810million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as
achondroplasia. Also in July, Pfizer acquired
Array Biopharma for $10.6billion, boosting its oncology pipeline. In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a
joint venture owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a
public company. The transaction built on a 2018 transaction where GlaxoSmithKline acquired
Novartis' stake in the GSK-Novartis consumer healthcare joint business. The transaction followed negotiations with other companies including
Johnson & Johnson, and
Procter & Gamble. In September 2019, Pfizer initiated a study with the
CDC Foundation to investigate the tracking of
healthcare-associated infections, scheduled to run through to June 2023. In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its
cryptococcal disease screening and treatment research in nine African countries.
In September 2020, the company acquired a 9.9% stake in
CStone Pharmaceuticals for $200million (HK$1.55billion), helping to commercialise its anti-
PD-L1 monoclonal antibody, CS1001. In October 2020, the company acquired Arixa Pharmaceuticals. In November 2020, using a
Reverse Morris Trust structure, Pfizer merged its off-patent branded and
generic drug business, known as Upjohn, with
Mylan to form
Viatris, owned 57% by Pfizer shareholders.
2021–onwards: Corporate developments and acquisitions
On January 5, 2021, Pfizer introduced a new
logo. In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound
fosmanogepix (APX001). In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion ($18.50 per share). In December, Pfizer announced that it had agreed to acquire
Arena Pharmaceuticals for $6.7 billion in cash. In March 2022, it was announced the acquisition of Arena Pharmaceuticals had been concluded. In April 2022, the company announced it would acquire ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat
respiratory syncytial virus infections. Pfizer completed the acquisition of ReViral in June 2022.
In October 2022, the company completed the acquisition of
Biohaven Pharma and its
calcitonin gene-related peptide programs for $11.6 billion. In August 2022, the company announced it would buy Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business and helping with its aim to add $25 billion in revenue by 2030.
The following month, the
Foundation for the National Institutes of Health announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products. Pfizer joined the partnership as an industry "leadership organization", and participated as a collaborator in ACTIV-led clinical trials. CEO
Albert Bourla attended the
GAVICOVAX AMC 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on April 15, 2021.
In Canada, Pfizer endorsed the use of a
vaccine passportmobile app developed by CANImmunize in order to record and track status of COVID-19 vaccination.
As the scale of the
COVID-19 pandemic became apparent, Pfizer partnered with BioNTech to study and develop
COVID-19 mRNA vaccine candidates. Unlike many of its competitors, Pfizer took no initial research funds from the United States'
Operation Warp Speed vaccine development program, instead choosing to invest roughly $2 billion of its own funds. Pfizer CEO Albert Bourla has said that he declined money from Operation Warp Speed to avoid government intervention, stating later that "when you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. And also, I wanted to keep Pfizer out of politics, by the way."
In May 2020, Pfizer began testing four different
COVID-19 vaccine variations using
lipid nanoparticle technology provided by Canadian biotechnology company
Acuitas Therapeutics. Vaccines were injected into the first human participants in the U.S. in early May. In July 2020, Pfizer and BioNTech announced that two of the partners' four
mRNA vaccine candidates had won fast track designation from the
FDA. The company began PhaseII-III testing on 30,000 people in the last week of July 2020 and was slated to be paid $1.95billion for 100million doses of the vaccine by the US government. The U.S. deal priced two doses at $39, and the company stated that it would not lower the rates for other countries until the outbreak is no longer a pandemic. Pfizer's CEO stated the companies in the private sector producing a vaccine should make a profit. In September 2020, Pfizer and BioNTech announced that they had completed talks with the European Commission to provide an initial 200million vaccine doses to the EU, with the option to supply another 100million doses at a later date.
On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19. The efficacy was updated to 95% a week later. Akiko Iwasaki, an immunologist interviewed by the New York Times, described the efficacy figure as "really a spectacular number." The announcement made Pfizer and BioNTech the first companies to develop and test a working vaccine for COVID-19.
Over the following month and a half, regulators in various countries approved Pfizer's vaccine for emergency use. The United Kingdom approved the vaccine first, on December 2, followed by
Bahrain on December 4, Canada on December 9, and Saudi Arabia on December 10. On December 10, 2020, the United States FDA held an advisory committee meeting to discuss authorization of the vaccine. The next day, the US officially became the 5th country to approve use of Pfizer's vaccine under an Emergency Use Authorization (EUA), with an independent panel voting 17–4 in support of approval. On December 14, Singapore became one of the first in Asia to approve the vaccine through the
Health Sciences Authority. On December 21, the
European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for the vaccine in the
European Union, under the brand name "Comirnaty."
As of early May 2021, Pfizer and BioNTech had manufactured at least 430 million vaccine doses, which have been distributed to 91 countries and territories. The companies have said they expect to manufacture nearly 3 billion total vaccine doses in 2021. Pfizer provided 0.9%
Sodium chloride Injection USP diluent for use with the
Pfizer–BioNTech COVID-19 vaccine under the name of its subsidiary,
Hospira. Pfizer also purchased large quantities of single-use medical and
surgical gloves and protective bodysuits from
Ansell during the process, contributing to a doubling of the supplier's manufacturing capacity.
In February 2021, after a year long investigation relying on unnamed officials, Pfizer was accused by
The Bureau of Investigative Journalism (TBIJ) of employing "high-level bullying" against at least two
Latin American countries during negotiations to acquire COVID-19 vaccines, including requesting that the countries put sovereign assets as
collateral for payments. According to TBIJ, these negotiation tactics resulted in a months long delay in Pfizer reaching a vaccine agreement with one country and a complete failure to reach agreements with two other countries, including
Argentina and Brazil.
On 2 November 2021, TBMJ published an article after obtaining information from a
whistleblower from the Ventavia Research Group. Ventavia was hired by Pfizer as a research subcontractor. The company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in
Pfizer's pivotal phase III trial. The regional director, Brook Jackson, emailed a complaint to the US
Food and Drug Administration (FDA). Ventavia fired her later the same day. The
European Medicines Agency (EMA) stated in a response to the
European Parliament, that "the deficiencies identified do not jeopardize the quality and integrity of the data from the main Comirnaty trial and have no impact on the benefit-risk assessment or on the conclusions on the safety, effectiveness and quality of the vaccine".
On 10 October 2022, during a session of the
European Parliament's Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated their
COVID-19 vaccine for its ability to reduce transmission of the
SARS-CoV-2 virus prior to its release to the general public. Dutch MEP
Rob Roos described the admission as "scandalous". CEO
Albert Bourla was slated to attend, but withdrew. Roos' statements in turn have been described as "misleading".
Development of oral antivirals
In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as
Paxlovid. In January 2022, the Pfizer CEO
Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company,
Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President
Joe Biden and Dr.
Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
In September 2009, Pfizer pleaded guilty to the illegal marketing of
valdecoxib (Bextra) and agreed to a $2.3billion settlement, the largest
health care fraud settlement at that time. Pfizer promoted the sale of the drug for several uses and dosages that the
Food and Drug Administration specifically declined to approve due to safety concerns. The drug was pulled from the market in 2005. It was Pfizer's fourth such settlement in a decade. The payment included $1.195billion in criminal penalties for felony violations of the
Federal Food, Drug, and Cosmetic Act, and $1.0billion to settle allegations it had illegally promoted the drugs for uses that were not approved by the
Food and Drug Administration (FDA) leading to violations under the
False Claims Act as reimbursements were requested from Federal and State programs. The criminal fine was the largest ever assessed in the United States to date. Pfizer entered a
corporate integrity agreement with the
Office of Inspector General that required it to make substantial structural reforms within the company, and publish to its website its post approval commitments and a searchable database of all payments to physicians made by the company.
Termination of Peter Rost
Peter Rost was vice president in charge of the
endocrinology division at
Pharmacia before its acquisition by Pfizer. During that time he raised concerns internally about
kickbacks and off-label marketing of Genotropin, Pharmacia's
human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.
Illegal marketing of Rapamune
A "whistleblower suit" was filed in 2005 against
Wyeth, which was acquired by Pfizer in 2009, alleging that the company illegally marketed
sirolimus (Rapamune) for
off-label uses, targeted specific doctors and medical facilities to increase sales of Rapamune, tried to get transplant patients to change from their transplant drugs to Rapamune, and specifically targeted
African-Americans. According to the whistleblowers, Wyeth also provided doctors and hospitals that prescribed the drug with kickbacks such as grants, donations, and other money. In 2013, the company pleaded guilty to criminal mis-branding violations under the
Federal Food, Drug, and Cosmetic Act. By August 2014, it had paid $491million in civil and criminal penalties related to Rapamune.
In June 2010, health insurance network
Blue Cross Blue Shield (BCBS) filed a lawsuit against Pfizer for allegedly illegally marketing drugs Bextra, Geodon and Lyrica. BCBS alleged that Pfizer used kickbacks and wrongly persuaded doctors to prescribe the drugs. According to the lawsuit, Pfizer handed out 'misleading' materials on
off-label uses, sent over 5,000 doctors on trips to the
Caribbean or around the United States, and paid them $2,000 honoraria in return for listening to lectures about Bextra. Despite Pfizer's claims that "the company's intent was pure" in fostering a legal exchange of information among doctors, an internal marketing plan revealed that Pfizer intended to train physicians "to serve as public relations spokespeople." The case was settled in 2014 for $325million. Fearing that Pfizer is "
too big to fail" and that prosecuting the company would result in disruptions to
Medicaid, federal prosecutors instead charged a subsidiary of a subsidiary of a subsidiary of Pfizer, which is "nothing more than a shell company whose only function is to plead guilty."
The Quigley Company, which sold
asbestos-containing insulation products until the early 1970s, was acquired by Pfizer in 1968. In June 2013, asbestos victims and Pfizer negotiated a settlement that required Pfizer to pay a total of $964million: $430million to 80% of existing plaintiffs and place an additional $535million into a settlement trust that will compensate future plaintiffs as well as the remaining 20% of plaintiffs with claims against Pfizer and Quigley. Of that $535million, $405million is in a 40-year note from Pfizer, while $100million is from insurance policies.
Shiley defective heart valves
Pfizer purchased Shiley in 1979, at the onset of its Convexo-Concave valve ordeal, involving the
Bjork–Shiley valve. Approximately 500 people died when defective
heart valves fractured and, in 1994, Pfizer agreed to pay $10.75million to settle claims by the
United States Department of Justice that the company lied to get approval for the valves.
Firing of employee that filed suit
A federal lawsuit was filed by a scientist claiming she got an infection by a genetically modified
lentivirus while working for Pfizer, resulting in intermittent
paralysis. A judge dismissed the case citing a lack of evidence that the illness was caused by the virus but the jury ruled that by firing the employee, Pfizer violated laws protecting
freedom of speech and
whistleblowers and awarded her $1.37million.
Celebrex intellectual property
Brigham Young University (BYU) said a professor of chemistry, Dr.
Daniel L. Simmons, discovered an enzyme in the 1990s that led towards development of
Celebrex. BYU was originally seeking a 15% royalty on sales, equating to $9.7billion. A research agreement had been made between BYU and
Monsanto, whose pharmaceutical business was later acquired by Pfizer, to develop a better
aspirin. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450million.
In 1996, an outbreak of measles, cholera, and bacterial meningitis occurred in Nigeria. Pfizer representatives and personnel from a contract research organization (CRO) traveled to
Kano to set up a clinical trial and administer an experimental
trovafloxacin, to approximately 200 children. Local Kano officials reported that more than fifty children died in the experiment, while many others developed mental and physical deformities. The nature and frequency of both fatalities and other adverse outcomes were similar to those historically found among pediatric patients treated for meningitis in sub-Saharan Africa. In 2001, families of the children, as well as the governments of Kano and Nigeria, filed lawsuits regarding the treatment. According to Democracy Now!, "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug." The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval.
In 2007, Pfizer published a Statement of Defense letter. The letter stated that the drug's oral form was safer and easier to administer, that Trovan had been used safely in more than five thousand Americans prior to the Nigerian trial, that mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics, and that no unusual side effects, unrelated to meningitis, were observed after four weeks.
In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed.
In December 2010, a
United States diplomatic cables leak was released by
WikiLeaks indicating that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general Aondoakaa to persuade him to drop legal action.The Washington Post reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail". In response, the company released a press statement describing the allegations as "preposterous" and saying that it acted in good faith. Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case, was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010.
The lawsuits were eventually settled out of court. Pfizer committed to paying US$35 million "to compensate the families of children in the study", another US$30 million to "support healthcare initiatives in Kano", and 10 million to cover legal costs. Payouts began in 2011.
In July 2022, UK antitrust authorities fined Pfizer £63 million for unfairly high priced drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company took advantage of loopholes by de-branding epilepsy drug Epanutin, by doing so the price of Epanutin's price was not regulated to the same standards the company are used to and therefore the price of the drug was raised. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.
Allegations of patent infringement on mRNA technology
Pfizer has inherited Wyeth's liabilities in the
American Cyanamid site in
Bridgewater Township, New Jersey, a highly toxic EPA
Superfund site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses. The
Sierra Club and the
Edison Wetlands Association have opposed the cleanup plan, arguing that the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking
contaminated soil off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS.
In June 2002, a chemical explosion at the Groton plant injured 7 people and caused the evacuation of more than 100 homes in the surrounding area.
Pfizer has been a major donor to the
National Press Foundation. Pfizer sponsored a program for the NPF called "Cancer Issues 2010" to train journalists to "understand the latest research" on various cancers, including the role of pharmaceutical products and vaccines.
MicroRNA (miRNA) was also a listed topic.
19 to Zero, a "coalition of academics, public health experts, behavioural economists, and creative professionals" that develops media and educational materials to influence public perception surrounding
Pfizer lobbied various officials in the
Government of British Columbia between April and November 2012, including then-premier
Christy Clark, future premier
John Horgan, future health minister
Adrian Dix, and future deputy premier, minister of public safety and solicitor general
Mike Farnworth. The disclosed purpose was to "provide health policy and pharmaceutical information and communications on behalf of Pfizer Canada," and "learn and understand the budgetary, policy and strategic directions of the Government."
Bioscience Association Manitoba (BAM) - Sponsor.
British Columbia Pharmacy Association (BCPA) - Event sponsor.
Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) - Patron (former).
In 2020, Pfizer provided funding in the range of $100,000.00 - $250,000.00 to
Ronald McDonald House Charities “to provide resources that directly improve the health and well-being of children and their families.”
Research and development
Pfizer has partnered with and sponsored many medical research networks and professional associations in the United States, Canada and globally:
ABC Global Alliance - Main sponsor. The alliance is a Portuguese not-for-profit society supporting research into advanced breast cancer.
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) - Industry partner.
^Iftikhar, I. H.; Alghothani, L.; Trotti, L. M. (December 2017). "Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis". European Journal of Neurology. 24 (12): 1446–1456.